Namibia guideline for submission of applications for registration of pharmaceuticals for human use in common technical document format.
Medicines and Allied Substances [No. 3 of 2013 47 | An Act to continue the existence of the Pharmaceutical Regulatory Authority and re-name it as the Zambia Medicines Regulatory Authority; provide f...or the functions and powers of the Authority; provide for the registration and regulation of pharmacies, health shops and agro-veterinary shops; provide for the registration and regulation of medicines and allied substances; provide for the regulation of the manufacture, importation, exportation, possession, storage, distribution, supply, promotion, advertising, sale and use of medicines and allied substances; provide for the regulation and control of clinical trials; repeal and replace the Pharmaceutical Act, 2004; and provide for matters connected with, or incidental to, the foregoing.
more
PQM conducted an assessment of the medicine quality assurance and quality control systems in Rwanda during November 9-13, 2009. Medicine quality assurance remains to be developed in Rwanda: the coun...try has neither a medicine regulatory authority (MRA) nor a national medicine quality control laboratory – the two key institutions to ensure the quality, safety, and efficacy of medicines. The MOH Pharmacy Taskforce (PTF) is to be commended however for successfully controlling the pharmaceutical market to the extent that there is no informal medicines market in Rwanda. Based on its findings, the assessment team expects Rwanda to be able to make great strides in evidence-based medicines quality assurance in the short to medium term, provided it receives adequate technical assistance and financial support.
more
Q9: Antidepressant medicines in individuals with a depressive episode in bipolar disorder1Q9: In individuals presenting with a depressive episode in bipolar disorder, are antidepressant medicines ef...fective and safe?
more
WHO today published the new edition of its Model Lists of Essential Medicines and Essential Medicines for Children, which include new treatments for various cancers, insulin analogues and new oral <...span class="attribute-to-highlight medbox">medicines for diabetes, new medicines to assist people who want to stop smoking, and new antimicrobials to treat serious bacterial and fungal infections.
The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all. However, high prices for both new, patented medicines and older medicines, like insulin, continue to keep some essential medicines out of reach for many patients.
more
Report of the 23rd WHO Expert Committee on the selection and use of essential medicines
This executive summary reports the recommendations made by the Expert Committee for the 2021 update of the WHO Model List of Essential ...-highlight medbox">Medicines (EML) and the Model List of Essential Medicine for Children (EMLc).
The 23rd meeting of the WHO Expert Committee on Selection and Use of Essential Medicines was coordinated from Geneva, Switzerland, and held virtually from 21 June to 2 July 2021. The Committee considered 88 applications proposing additions, changes and deletions of medicines, medicine classes and formulation on the Model Lists of Essential Medicines. The Committee evaluated the scientific evidence for comparative effectiveness, safety and cost-effectiveness of the medicines in question. The Committee also considered a review of the therapeutic alternatives for medicines on the Model Lists, and update to the AWaRe classification of antibiotics, and reviews and reports relevant to the selection and use of essential medicines.
more
The document describes the use of strategic information at various stages of the response in the context of strengthening broader health information systems. Strategic ...light medbox">information can be defined as data collected at all service delivery and administrative levels to inform policy and programme decisions.
more
Technical Report
AIDS Medicines and diagnostics service
July 2015
Produced by Training and Research Support Centre for the Regional Network for Equity in Health in east and southern Africa (EQUINET), March 20, 2020.
This brief summarises and provides links to official, scientific and other resources to support an understanding of and individual to regional level... responses to the epidemic of ‘novel coronavirus’, also known as COVID-19.
more
People living with HIV depend on life-saving antiretroviral therapy (ART) and access to ART must be maintained during periods of travel restrictions and lockdowns resulting from the COVID-19 pandemic. The Information note on HIV and COVID-19 address...es common concerns people living with HIV have regarding the risks of COVID-19 and how to minimize them. For HIV programme managers and health facilities providing HIV services, it identifies key points related to ensuring uninterrupted provision of ART, while protecting clients and staff from the risk of infection with the SARS-CoV-2 virus.
more
This statement aims to provide guidance and recommendation to African Union Member States in responding to the following questions:
What should countries do when announcing identification of a herbal remedy or medicine?
What are the implic...ations for the rest of the continent?
more
5 May 2021
This Information Note is intended to assist national TB programmes and health personnel worldwide to maintain essential tuberculosis (TB) services during the COVID-19 pandemic and in the recovery phase. It is important that recent progre...ss made in TB prevention and care is not reversed by COVID-19. The WHO Global TB Programme, along with WHO regional and country offices, developed this note in response to questions received from Member States and other partners since the start of the pandemic. The note includes references to other published WHO information products relevant to TB practitioners. WHO continues to monitor the situation closely for any changes that may influence this note and will issue updates should any factors change.
more
Annex 5, WHO Technical Report Series 1010, 2018
Med J DY Patil Univ 2017;10:229-33